Ionis Pharmaceuticals Inc (NAS:IONS)
$ 38.8 -0.28 (-0.72%) Market Cap: 5.66 Bil Enterprise Value: 4.94 Bil PE Ratio: 0 PB Ratio: 19.11 GF Score: 74/100

Ionis Pharmaceuticals Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript

Sep 22, 2020 / 06:30PM GMT
Release Date Price: $50.77 (+1.14%)
Kevin Michael DeGeeter
Oppenheimer & Co. Inc., Research Division - MD & Senior Analyst

All right. I want to thank everyone for joining us. So the next company presenting is Ionis Pharmaceuticals. My name is Kevin DeGeeter. I'm a biotech analyst here with Oppenheimer, joined by several of my Oppenheimer colleagues and some of the folks from Ionis.

I think the way we're going to do this is sort of Q&A format. So very much looking forward to that. If you do you have any specific questions, of course, you can e-mail them to me directly. I think most of you have my mail, but [email protected] as well, or I think directly Q&A chat box.

Questions & Answers

Kevin Michael DeGeeter
Oppenheimer & Co. Inc., Research Division - MD & Senior Analyst

With that out of the way, I guess, maybe we'll do a couple of the housekeeping items upfront. Akcea, a very, I think, strategic transaction, the company announced a little over 2 weeks ago now. Just kind of any update you can provide if there is one with regard to time line to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot